Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed\/refractory T-ALL: a phase 1 test

.Attribute Medicine, Released online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a period 1 trial.

Articles You Can Be Interested In

• Privacy
• Teamwork
• Public Speaking
• Volunteering
• Career Advice
• Psychology
• Science
• Legal Advice
• Nutrition
• Biotech
• Retail
• Music Trends
• Parenting
• Manufacturing
• Manufacturing
• Nanotechnology
• UX/UI Design
• Nanotechnology
• Self-Help
• Legal Advice